{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-018514","form_type":"8-K","ticker":null,"cik":"0001860782","company_name":"2seventy bio, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.224951+00:00","generated_at":"2026-05-21T18:14:04.118615+00:00","sec_items":["1.02","2.01","3.01","3.03","5.01","5.03","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Bristol-Myers Squibb completes acquisition of 2seventy bio for $5.00/share, total ~$264.6M","bullets":["Tender offer expired May 12, 2025; 81.8% of shares tendered (43,542,774 shares).","Merger completed May 13, 2025 without stockholder vote under DGCL Section 251(h).","All outstanding shares converted to $5.00 cash; total consideration ~$264.6M.","2seventy bio stock delisted from Nasdaq; plans to file Form 15 to suspend SEC reporting.","Board replaced with Bristol-Myers appointees; former directors resigned, stock plans terminated."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-018514","json":"https://secwatch.observer/filing/0001140361-25-018514.json","markdown":"https://secwatch.observer/filing/0001140361-25-018514.md","text":"https://secwatch.observer/filing/0001140361-25-018514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860782/000114036125018514/0001140361-25-018514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860782/000114036125018514/ny20048433x3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T18:14:04.118615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6c6ad89ed514166e9e2d0d0beefc8da2ef57d334","claim":"2seventy bio, Inc.: Amended and restated certificate of incorporation in connection with merger.","evidence_excerpt":"2seventy bio’s certificate of incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety (as so amended and restated, the “ Second Amended and Restated Certificate of Incorporation ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860782/000114036125018514/0001140361-25-018514-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"8a171cb885f1561a25b4bef67a2827ac6c1e4877","claim":"2seventy bio, Inc.: Amended and restated by-laws in connection with merger.","evidence_excerpt":"2seventy bio’s by-laws, as in effect immediately prior to the Effective Time, were amended and restated in their entirety (as so amended and restated, the “ Second Amended and Restated By-Laws ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860782/000114036125018514/0001140361-25-018514-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"019c6efab16d327c92320e7b552f49c0e2390c28","claim":"2seventy bio, Inc. underwent a change of control involving Bristol-Myers Squibb Company for $5.00 per share in cash (closed 2025-05-13).","evidence_excerpt":"ities and Exchange Commission (the “ SEC ”) on March 11, 2025 by 2seventy bio, Inc., a Delaware corporation (the “ Company ” or “ 2seventy bio ”), 2seventy bio entered into an Agreement and Plan of Merger, dated March 10, 2025 (the “ Merger Agreement ”), with Bristol-Myers Squibb Company, a Delaware corporation (“ Bristol-Myers Squibb ”), and Daybreak","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860782/000114036125018514/0001140361-25-018514-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Bristol-Myers Squibb Company"},{"label":"Consideration","value":"$5.00 per share in cash"},{"label":"Closing","value":"2025-05-13"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}